DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
52 hedge funds and large institutions have $12.1M invested in DMK Pharmaceuticals Corporation Common Stock in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 12 closing their positions.
64% more call options, than puts
Call options by funds: $834K | Put options by funds: $508K
10% less funds holding
Funds holding: 58 → 52 (-6)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
32% less capital invested
Capital invested by funds: $18M → $12.1M (-$5.81M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$874K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$262K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$176K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$162K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$1.02M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.01M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$972K |
| 4 |
VF
Virtu Financial
New York
|
-$442K |
| 5 |
Barclays
London,
United Kingdom
|
-$391K |
DMK Hedge Fund Activity: Q1 2018 in Review
52 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2018, worth a combined $12.1M — down 32% from $18M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DMK and 6 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Morgan Stanley, adding an estimated $874K. The largest seller was B. Riley Financial, exiting entirely with an estimated $1.02M sold.
- 52 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2018, down from 58 in Q4 2017.
- Funds reported $12.1M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2018, down 32% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2018 and 12 closed out, a net change of -6 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2018 was Morgan Stanley, an estimated $874K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2018 was B. Riley Financial, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2018.